TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04071158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Tetanus, Diphtheria, and Acellular Pertussis Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Tetanus, Diphtheria, and Acellular Pertussis Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tdap
Description: Tetanus, Diphtheria, and Acellular Pertussis Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution for injection (0.9% sodium chloride injection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution for injection (0.9% sodium chloride injection)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution for injection (0.9% sodium chloride injection)
Study: NCT03439930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: 6 weeks lasting balance training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: 6 weeks lasting balance training program
Study: NCT04138680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Biofeedback
Description: The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Biofeedback
Description: The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
Study: NCT00773773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Description: Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Study: NCT02395523

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV
Study: NCT02974049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole
Study: NCT02908815

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS sham treatment
Description: A fake treatment designed to mimic the sensations of rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS sham treatment
Description: A fake treatment designed to mimic the sensations of rTMS
Study: NCT03707249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injectable Product
Description: iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: 250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
Study: NCT00876291

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG (probiotic )
Description: LGG capsules: each cp containing 3 × 109 colony forming units, CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
Study: NCT03946072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transseptal Aortic Approach Catheter Ablation Procedure
Description: The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Aortic Approach Catheter Ablation Procedure
Description: The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
Study: NCT02974049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Subjects in Arms 1 and 4 will receive 200mg/kg body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Subjects in Arms 1 and 4 will receive 200mg/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
Study: NCT02599779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
Study: NCT01211314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine/enalapril fixed combination
Description: Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
Study: NCT02210416

Intervention type: PROCEDURE
Intervention: inguinal hernia surgery

Intervention type: PROCEDURE
Intervention: inguinal hernia surgery
Study: NCT00979225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Management report
Description: Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Management report
Description: Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care manager email notices
Description: Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
Study: NCT01895946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
Study: NCT02583555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interview followed by frequent telephone support
Description: Interview followed by telephone support
Study: NCT02409719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schedule
Description: Illustrative daily planner to point the day that the exercise was performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Information and Booklet
Description: Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Information and Booklet
Description: Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
Study: NCT01376414

Intervention type: OTHER
Intervention: Urea Breath Test (UBT) for H. pylori infection
Description: 13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
Study: NCT03262636

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: Indocyanine Green

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: Indocyanine Green
Study: NCT00866814

Intervention type: DEVICE
Intervention: Bard Ventrio Hernia Patch
Description: The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
Study: NCT02103972

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GM080

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT03180970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2% Lugol's solution
Description: 1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT01648049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (CBT)
Description: CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein \& Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, \& Dick, 1995).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard Care - Treatment as usual
Study: NCT04617145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
Study: NCT03723902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy-load strength training
Description: Three weekly sessions of heavy-load strength training for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Daily supplementation of 2 x 17 grams of milk protein
Study: NCT02122484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
Study: NCT00907933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 0.5mg intranasal SB-705498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 1.5mg intranasal SB-705498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 3mg intranasal SB-705498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 6mg intranasal SB-705498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intranasal SB-705498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo '498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 6mg intranasal SB-705498 for 14 days bid
Study: NCT03476369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Premedicated with Fentanyl (at least 25mcg by IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Premedicated with Fentanyl (at least 25mcg by IV)
Study: NCT00907933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intranasal SB-705498 14 days bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04389554

Intervention type: OTHER
Intervention: Blood D-dimer assay
Description: Blood samples will be taken from the patients and will be examined by the ELISA method.
Study: NCT03180970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% Lugol's solution
Description: 1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% Lugol's solution
Description: 0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% Lugol's solution
Description: 0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% Lugol's solution
Description: 0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Study: NCT04520724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant fiber
Description: The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin bar
Description: The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
Study: NCT03393949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1 mg•kg-1
Description: Patients in Group M received methylprednisolone 1mg•kg-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline 1mg•kg-1
Description: Patients in Group C received isotonic saline 1mg•kg-1
Study: NCT03476369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90Mg Tablet
Description: Ticagrelor administered crushed vs non-crushed
Study: NCT00705146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfort Cool thumb splint by North Coast Medical
Description: Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom made thermoplastic & neoprene splint
Description: The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
Study: NCT03246659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-CP04
Description: Radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-CP04 with co-administration of gelofusine/gelaspan
Description: Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
Study: NCT04530500

Intervention type: GENETIC
Intervention: COVID-19 Androgen Sensitivity Test (CoVAST)
Description: The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.

Intervention type: GENETIC
Intervention: COVID-19 Androgen Sensitivity Test (CoVAST)
Description: The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
Study: NCT00534833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-PRP~T vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib™
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: 0.5 mL, Oral

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Polio Vaccine
Description: 0.5 mL, Oral